Browse news and features about Oxford Nanopore Technologies – a company founded in 2005 to develop a disruptive, electronic, single-molecule sensing system based on nanopore science. The company’s novel, electronics-based DNA/RNA sequencing technology is now used in nearly 100 countries for a range of biological research applications.
Oxford Nanopore and Day Zero Diagnostics have announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.
The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
The test is fully scalable and designed to enable both high-volume screening and rapid, local testing, and results can be obtained in under two hours.
Oxford Nanopore Technologies has raised £48.4M ($59.2M) in new capital from new investors and existing shareholders in EMEA, US and Asia.
Oxford Nanopore is working with public health laboratories around the world, and researchers in related areas, to support the current COVID-19 pandemic.
Oxford Nanopore Technologies raises £109.5m in investment and share sales with £29.3m of new capital and £80.2m from sale of secondary shares.